|
Kowa Pharmaceuticals America |
|
|
530 Industrial Park Blvd.
Montgomery, AL 36117 United States
phone:(334) 288-1288
fax:(334) 288-2788
|
|
| Symbol |
|
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.kowapharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Kowa Pharma is a specialty pharmaceutical focused on cardiology and pain relief. |
|
| Management |
| Ben Stakely, CEO and President; Torao Yamamoto, Senior Managing Director, General Manager of Pharmaceutical Division, Kowa Company, Ltd.; Dr. Junichi Kawagoe,
Director, Licensing Department, Kowa Company, Ltd.; Dr. Claus K?hl, President, Kowa Research Institute, Inc.; Charles Smith, RPh, Founding Member, ProEthic Pharmaceuticals, Inc. |
| |
|
|
|
|
|
| Keywords |
| cardiology, cholesterol, migraine, pain, pain relief, pharmaceuticals |
|
|
|
| Description |
|
In July of 2008, Kowa Company, Ltd., of Nagoya, Japan, acquired ProEthic Pharmaceuticals, Inc., and Kowa Pharmaceuticals America, Inc. (KPA) was born.
KPA is a specialty pharmaceutical company focused primarily in the areas of cardiology, pain, and migraine. The privately held company focuses its efforts on the acquisition, development, licensing, and marketing of pharmaceutical products. |
|
| Products / Services |
The first pharmaceutical product to be launched by KPA will be pitavastatin, a novel HMG CoA reductase inhibitor for the treatment of hyperlipidemia. Pitavastatin has recently completed Phase 3 clinical development in Europe and the United States.
In June 2009, KPA receive approval from the U.S. Food and Drug Administration for Cambia, a diclofenac-based NSAID combined with potassium carbonate to treat migraines with or without auras in adults.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
